Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 8/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.63 |
| ▸ | HTT | P42858 | 5/20 | 0.63 |
| ▸ | HPGD | P15428 | 3/20 | 0.63 |
| ▸ | GAA | P10253 | 2/20 | 0.63 |
| ▸ | RECQL | P46063 | 2/20 | 0.60 |
| ▸ | LMNA | P02545 | 4/20 | 0.57 |
| ▸ | RAB9A | P51151 | 5/20 | 0.57 |
| ▸ | P4HB | P07237 | 3/20 | 0.55 |
| ▸ | NPC1 | O15118 | 3/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.49 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.46 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.46 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4256806 | 1.00 | MAPT (0.63) | MAPTALDH1A1HTTHPGDGAA | |
| SCHEMBL5946453 | 0.88 | MAPT (0.77) | MAPTALDH1A1HTTHPGDGAA | |
| SCHEMBL950110 | 0.83 | MAPT (0.70) | MAPTALDH1A1HTTHPGDGAA | |
| SCHEMBL950108 | 0.83 | MAPT (0.70) | MAPTALDH1A1HTTHPGDGAA | |
| SCHEMBL22449502 | 0.82 | RECQL (0.71) | MAPTALDH1A1HTTHPGDGAA | |
| SCHEMBL5800440 | 0.82 | RECQL (0.71) | MAPTALDH1A1HTTHPGDGAA | |
| SCHEMBL2162785 | 0.81 | MAPT (0.71) | MAPTALDH1A1HTTHPGDGAA | |
| SCHEMBL17354036 | 0.81 | MAPT (0.63) | MAPTALDH1A1HTTHPGDGAA | |
| SCHEMBL14537314 | 0.81 | MAPT (0.71) | MAPTALDH1A1HTTHPGDGAA | |
| SCHEMBL16024024 | 0.81 | MAPT (0.63) | MAPTALDH1A1HTTHPGDGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110407833-B | Deuterated Vissturtib compound and application thereof | 海创药业股份有限公司 | 2021-03-09 | — | — | CN | disclosed |
| US-20090270435-A1 | Spiroketone Acetyl-CoA Carboxylase Inhibitors | CORBETT JEFFREY WAYNE | 2009-10-29 | — | — | US | disclosed |
| EP-2097420-A1 | SPIROKETONE ACETYL-COA CARBOXYLASE INHIBITORS | Pfizer Products Inc. (US) | 2009-09-09 | — | — | EP | disclosed |
| WO-2008065508-A1 | SPIROKETONE ACETYL-COA CARBOXYLASE INHIBITORS | PFIZER PRODUCTS INC. (US) | 2008-06-05 | — | — | WO | disclosed |
| US-20060063784-A1 | Method of using substituted pyrazolo [1,5-a] pyrimidines | WYETH | 2006-03-23 | — | — | US | disclosed |
| US-20060063785-A1 | Substituted pyrazolo[1,5-a] pyrimidines and process for making same | WYETH | 2006-03-23 | — | — | US | disclosed |
| EP-0699185-B1 | GUANIDINE DERIVATIVES AS INHIBITORS OF Na+ /H+ EXCHANGE IN CELLS | FUJISAWA PHARMACEUTICAL CO (JP) | 2001-09-05 | — | — | EP | disclosed |
| US-5824691-A | CARDIOVASCULAR, CEREBROVASCULAR, RENAL DISEASES; SHOCK, ARTERIOSCLEROSIS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1998-10-20 | — | — | US | disclosed |
| EP-0699185-A1 | GUANIDINE DERIVATIVES AS INHIBITORS OF Na+ /H+ EXCHANGE IN CELLS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1996-03-06 | — | — | EP | disclosed |
| WO-1994026709-A1 | GUANIDINE DERIVATIVES AS INHIBITORS OF Na+/H+ EXCHANGE IN CELLS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1994-11-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060063785-A1 | Substituted pyrazolo[1,5-a] pyrimidines and process for making same | TYMP, DPYD, TYMS | MAPT 3174/4885ALDH1A1 848/4885HTT 2696/4885 |
| US-20090270435-A1 | Spiroketone Acetyl-CoA Carboxylase Inhibitors | ACACA, PC, ACACB | MAPT 2999/4885ALDH1A1 212/4885HTT 3371/4885 |
| US-20060063784-A1 | Method of using substituted pyrazolo [1,5-a] pyrimidines | TYMP, DPYD, TYMS | MAPT 4164/4885ALDH1A1 847/4885HTT 2314/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.